-+ 0.00%
-+ 0.00%
-+ 0.00%

Revvity Unveils SLAS2026 Platforms As Valuation Gap Attracts Attention

Simply Wall St·02/12/2026 01:21:15
Listen to the news
  • Revvity (NYSE:RVTY) introduced several new discovery platforms and technologies at SLAS2026.
  • The launches span high content screening, plate reading, and laboratory automation tools.
  • The new products are designed to support faster drug discovery and streamlined lab workflows.

Revvity, trading at around $101.1, is adding fresh products to its life sciences tools portfolio at a time when its 1 year return sits at a decline of 8.9% and its 3 year and 5 year returns show declines of 24.7% and 29.2% respectively. For investors tracking NYSE:RVTY, these launches at a major industry conference highlight how the company is positioning its technology stack in high content screening and automated lab workflows.

Going forward, you might watch how quickly these platforms gain traction with pharma, biotech, and academic labs, and whether they integrate into existing discovery workflows. Adoption patterns, recurring revenue potential, and any follow-up product iterations could all become useful signals for how meaningful SLAS2026 is for Revvity's broader tools franchise.

Stay updated on the most important news stories for Revvity by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Revvity.

NYSE:RVTY Earnings & Revenue Growth as at Feb 2026
NYSE:RVTY Earnings & Revenue Growth as at Feb 2026

We've flagged 1 risk for Revvity. See which could impact your investment.

Quick Assessment

  • ✅ Price vs Analyst Target: At US$101.10, the share price sits about 15% below the US$119.56 analyst target range midpoint.
  • ✅ Simply Wall St Valuation: Shares are described as trading 27.4% below estimated fair value, which flags a potential valuation gap.
  • ❌ Recent Momentum: The 30 day return of about 2.7% decline shows the market has been cautious recently.

There is only one way to know the right time to buy, sell or hold Revvity. Head to Simply Wall St's company report for the latest analysis of Revvity's Fair Value.

Key Considerations

  • 📊 The SLAS2026 platform launches sit alongside a relatively high P/E of 47.8 and life sciences positioning, so you may want to judge whether the product suite justifies that earnings multiple.
  • 📊 Watch how any commentary links new tools to revenue growth, recurring software or consumables, and whether analysts adjust the US$105 to US$140 target range.
  • ⚠️ One flagged risk is large one off items affecting reported earnings quality, which can make it harder to read the true impact of new platforms on profitability.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Revvity analysis. Alternatively, you can visit the community page for Revvity to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.